Treatment of Group B Streptococcal UTI in Pregnant Women

First-Line Treatment Options

• The American College of Obstetricians and Gynecologists recommends penicillin G (5 million units IV initially, then 2.5 million units IV every 4 hours) as the preferred agent for inpatient treatment due to its narrow spectrum of activity and high efficacy against GBS 1
• The Centers for Disease Control and Prevention suggests ampicillin (2 g IV initial dose, then 1 g IV every 4 hours) as an acceptable alternative for inpatient treatment 1
• Completing the full prescribed course of antibiotics is crucial to ensure complete eradication and prevent recurrence, as recommended by the American College of Obstetricians and Gynecologists 2

Treatment for Penicillin-Allergic Patients

• For patients with penicillin allergy who are not at high risk for anaphylaxis, the Centers for Disease Control and Prevention recommends cefazolin (2 g IV initial dose, then 1 g IV every 8 hours) as the preferred alternative 1
• For patients at high risk for anaphylaxis, clindamycin (900 mg IV every 8 hours) can be used if the isolate is confirmed susceptible, according to the Centers for Disease Control and Prevention 1
• If susceptibility testing is not available or the isolate is resistant to clindamycin, vancomycin (1 g IV every 12 hours) is recommended by the Centers for Disease Control and Prevention 1

Special Considerations for GBS in Pregnancy

• Women with GBS bacteriuria in any concentration during pregnancy should receive intrapartum antimicrobial prophylaxis during labor to prevent early-onset neonatal GBS disease, as recommended by the American College of Obstetricians and Gynecologists 2
• Women with GBS bacteriuria during pregnancy should still receive intrapartum antibiotic prophylaxis during labor regardless of whether they were treated earlier in pregnancy, according to the Centers for Disease Control and Prevention 3

Importance of Susceptibility Testing

• Susceptibility testing should be performed on GBS isolates from penicillin-allergic patients at high risk for anaphylaxis, as recommended by the American College of Obstetricians and Gynecologists 2
• Testing for inducible clindamycin resistance is necessary for isolates that are susceptible to clindamycin but resistant to erythromycin, according to the American College of Obstetricians and Gynecologists 4

Follow-up and Monitoring

• If GBS is detected in urine at ≥104 colony-forming units/ml, laboratories should report this finding as it indicates heavy colonization, as recommended by the Centers for Disease Control and Prevention 3
• Failure to provide intrapartum prophylaxis to women with previous GBS bacteriuria in pregnancy can increase the risk of early-onset neonatal GBS disease, according to the Centers for Disease Control and Prevention 3

Clinical Pitfalls and Caveats

• Underdosing or premature discontinuation of therapy may lead to treatment failure or recurrence, as warned by the American College of Obstetricians and Gynecologists 2
• Failure to provide intrapartum prophylaxis to women with previous GBS bacteriuria in pregnancy can increase the risk of early-onset neonatal GBS disease, according to the Centers for Disease Control and Prevention 3

Treatment for Positive Vaginal GBS Culture

Key Clinical Context

• The Centers for Disease Control and Prevention recommends that antimicrobial agents should not be used before the intrapartum period to treat GBS colonization, as such treatment is not effective in eliminating carriage or preventing neonatal disease and may cause adverse consequences 5, 6, 7, 8
• GBS colonization is only treated during active labor in pregnant women to prevent early-onset neonatal disease 8

When GBS Treatment IS Indicated

• The Centers for Disease Control and Prevention recommends that GBS urinary tract infection (symptomatic or asymptomatic) detected during pregnancy should be treated according to current standards for UTI in pregnancy 5, 6, 8
• Intrapartum antibiotic prophylaxis (during labor) is recommended for pregnant women who are GBS-positive on screening cultures at 35-37 weeks gestation 8
• Women with GBS bacteriuria at any concentration during pregnancy require both treatment of the UTI and intrapartum prophylaxis during labor 5, 6, 8

Management of Abnormal Vaginal Discharge

• The Centers for Disease Control and Prevention suggests that abnormal discharge should be evaluated for other treatable causes, such as bacterial vaginosis (Gardnerella, Mobiluncus) 7
• Candidiasis (yeast infection) and trichomoniasis should also be considered as potential causes of abnormal vaginal discharge 7
• Other pathogenic organisms may also be responsible for abnormal vaginal discharge 9

Critical Pitfall to Avoid

• The Centers for Disease Control and Prevention advises against treating asymptomatic GBS vaginal colonization outside of the intrapartum period, as it does not eliminate colonization effectively and may promote antibiotic resistance and cause adverse drug effects 5, 6, 7

If Patient is Pregnant

• The Centers for Disease Control and Prevention recommends screening for GBS colonization at 36 0/7 to 37 6/7 weeks gestation with vaginal-rectal culture 8
• Intrapartum antibiotic prophylaxis during labor is recommended if GBS-positive, with penicillin G 5 million units IV initially, then 2.5 million units IV every 4 hours until delivery 7, 9
• Alternative treatments for penicillin allergy are available, including cefazolin 2 g IV initially, then 1 g IV every 8 hours, or clindamycin 900 mg IV every 8 hours (if susceptible) or vancomycin 1 g IV every 12 hours 7, 9

Alternative Antibiotics for Group B Streptococcus Prophylaxis in Penicillin-Allergic Pregnant Women

Introduction to Guidelines

• The Centers for Disease Control and Prevention recommends that for pregnant women with penicillin allergy requiring GBS prophylaxis, cefazolin is the preferred alternative for those without high-risk allergy symptoms, while clindamycin (if susceptible) or vancomycin should be used for those at high risk for anaphylaxis 10, 11

Risk Stratification

• High-risk for anaphylaxis includes history of immediate hypersensitivity reactions (anaphylaxis, angioedema, or urticaria) and history of asthma or other conditions that would make anaphylaxis more dangerous 10
• Approximately 10% of persons with penicillin allergy also have immediate hypersensitivity reactions to cephalosporins, making this risk assessment essential 11

Treatment Algorithm

• For women not at high risk for anaphylaxis, cefazolin is the agent of choice 10, 11
• For women at high risk for anaphylaxis, the approach depends on susceptibility testing results, with clindamycin or vancomycin as alternatives 10, 11

Critical Importance of Susceptibility Testing

• Susceptibility testing for clindamycin and erythromycin must be performed on prenatal GBS isolates from penicillin-allergic women at high risk for anaphylaxis 10, 11

Special Considerations

• Pregnant women with reported penicillin allergy should undergo verification of their allergy history, as many reported penicillin allergies are not true IgE-mediated reactions 11
• Antimicrobial agents should NOT be used before the intrapartum period to treat GBS colonization, as such treatment is ineffective in eliminating carriage and may cause adverse consequences including resistance 10
• Only first-generation cephalosporins (cefazolin) should be used, as cefoxitin resistance has been reported among GBS isolates 10, 11
• Women undergoing planned cesarean delivery before labor/rupture of membranes should not routinely receive intrapartum chemoprophylaxis 10

Management of Group B Streptococcal Infections

Critical Context-Dependent Management

• The Centers for Disease Control and Prevention recommends that any concentration of GBS in urine during pregnancy requires immediate treatment and mandates intrapartum antibiotic prophylaxis during labor, regardless of whether the UTI was treated earlier in pregnancy 12
• Women with GBS bacteriuria are heavily colonized and at increased risk of delivering an infant with early-onset GBS disease, according to the Centers for Disease Control and Prevention 12
• The American Academy of Family Physicians notes that antimicrobial agents should not be used before the intrapartum period to treat GBS colonization, as treatment before labor is ineffective in eliminating carriage and may cause adverse consequences including antibiotic resistance 12, 13
• The Centers for Disease Control and Prevention recommends that women with GBS colonization should receive intrapartum antibiotic prophylaxis during labor, regardless of the colony count 12, 13

Special Pregnancy Scenarios

• The Centers for Disease Control and Prevention recommends that women admitted with signs and symptoms of preterm labor with unknown GBS status or positive GBS screen within 5 weeks should receive GBS prophylaxis immediately at hospital admission 14, 15
• The Centers for Disease Control and Prevention recommends that for women with PPROM at ≥24 weeks, antibiotics are strongly recommended for expectant management, and ampicillin 2 g IV once, followed by 1 g IV every 6 hours for at least 48 hours is adequate for both latency and GBS prophylaxis 14, 15

Treatment of GBS UTI in First Trimester Pregnancy

Importance of Immediate Treatment and Intrapartum Prophylaxis

• GBS bacteriuria at any concentration during pregnancy indicates heavy genital tract colonization and significantly increases the risk of early-onset neonatal GBS disease, according to the Centers for Disease Control and Prevention 16
• The Centers for Disease Control and Prevention recommends that treatment of the acute UTI does NOT eliminate GBS colonization from the genitourinary tract, and recolonization after antibiotics is typical 16
• Intrapartum antibiotic prophylaxis during labor reduces the risk of early-onset GBS disease by 78% if administered for ≥4 hours before delivery, as stated by the American College of Obstetricians and Gynecologists 17

Antibiotic Regimens and Management

• The American College of Obstetricians and Gynecologists recommends penicillin G as the agent of choice due to its narrow spectrum, universal GBS susceptibility, and proven efficacy, although the specific dosing is not cited 16
• The Centers for Disease Control and Prevention suggests that ampicillin is an acceptable alternative but has broader spectrum activity, however the citation for this fact is not provided

Intrapartum Prophylaxis

• The American College of Obstetricians and Gynecologists states that intrapartum antibiotic prophylaxis should be administered regardless of when the UTI was treated, with penicillin G or ampicillin preferred, or appropriate alternative for penicillin allergy, to reduce the risk of early-onset GBS disease 17

Treatment of GBS Bacteriuria

For Pregnant Women

• The Centers for Disease Control and Prevention (CDC) recommends that all pregnant women with GBS bacteriuria at any concentration, including 10,000-49,000 CFU/mL, must receive treatment at diagnosis followed by intrapartum prophylaxis during labor, regardless of symptoms 18
• GBS bacteriuria during pregnancy is a marker for heavy genital tract colonization and significantly increases the risk of early-onset neonatal GBS disease, with the CDC guidelines specifying that laboratories should report GBS present at ≥10^4 CFU/mL (10,000 CFU/mL) as the threshold for clinical significance in pregnancy 18

For Non-Pregnant Patients

• The Infectious Diseases Society of America (IDSA) provides strong evidence against screening for or treating asymptomatic bacteriuria in non-pregnant populations, and recommends that non-pregnant patients with GBS bacteriuria at 10,000-49,000 CFU/mL should not be treated unless they are symptomatic or have underlying urinary tract abnormalities 19
• The IDSA guidelines state that treating asymptomatic bacteriuria leads to unnecessary antibiotic exposure, resistance development, and potential adverse drug effects without clinical benefit, and that GBS in urine with colony counts 10,000-49,000 CFU/mL in asymptomatic non-pregnant patients represents asymptomatic bacteriuria that should not be treated 19

Treatment of Group B Streptococcus in Urine

Management of GBS Bacteriuria

• The Centers for Disease Control and Prevention recommends that any concentration of GBS in urine during pregnancy requires treatment because GBS bacteriuria is a marker for heavy genital tract colonization and significantly increases the risk of early-onset neonatal disease, with a concentration as low as 10,000 CFU/mL considered significant 20, 21
• The American College of Obstetricians and Gynecologists suggests that if the patient has symptomatic UTI, treat the acute infection immediately according to standard pregnancy UTI protocols using pregnancy-safe antibiotics, with guidelines recommending treatment based on susceptibility testing 22, 23
• The Centers for Disease Control and Prevention notes that treating the UTI during pregnancy does NOT eliminate GBS colonization from the genitourinary tract—recolonization after oral antibiotics is typical, which is why intrapartum IV prophylaxis remains mandatory even if bacteriuria was treated earlier in pregnancy, with a recommended IV antibiotic regimen administered ≥4 hours before delivery 20

Intrapartum Antibiotic Prophylaxis

• The American College of Obstetricians and Gynecologists recommends that all pregnant women with GBS bacteriuria at any point during the current pregnancy must receive intrapartum antibiotic prophylaxis during labor, regardless of when or if the UTI was treated, with first-line regimens including penicillin G or ampicillin 22, 23
• For patients with a penicillin allergy, the Infectious Diseases Society of America suggests alternative regimens, including cefazolin for patients not at high risk for anaphylaxis, and clindamycin or vancomycin for patients at high risk for anaphylaxis, with testing for inducible clindamycin resistance recommended 21

Prevention of Early-Onset Neonatal GBS Disease

• The Centers for Disease Control and Prevention states that intrapartum prophylaxis administered ≥4 hours before delivery is 78% effective in preventing early-onset neonatal GBS disease, emphasizing the importance of timely administration 20

Laboratory Reporting

• The Centers for Disease Control and Prevention recommends that laboratories are informed when urine specimens are from pregnant women so they report GBS at concentrations ≥10,000 CFU/mL (≥10^4 CFU/mL), ensuring appropriate management and prevention of neonatal disease 21

Management of Group B Streptococcus Urinary Tract Infections in Pregnant Women

Intrapartum Prophylaxis Requirements

• The Centers for Disease Control and Prevention recommends that all pregnant women with GBS bacteriuria at any concentration during any trimester of the current pregnancy must receive intrapartum IV antibiotic prophylaxis during labor, regardless of whether the UTI was treated earlier in pregnancy 24, 25
• Intrapartum prophylaxis administered ≥4 hours before delivery is effective in preventing early-onset neonatal GBS disease, with a reported efficacy of 78% 25

Intrapartum Prophylaxis Regimens

• The American College of Obstetricians and Gynecologists recommends penicillin G 5 million units IV initially, then 2.5 million units IV every 4 hours until delivery, as the preferred agent for intrapartum prophylaxis in women without penicillin allergy 24
• For penicillin-allergic patients, alternative regimens such as cefazolin, clindamycin, or vancomycin may be used, depending on the patient's risk of anaphylaxis and the susceptibility of the GBS isolate 25

Treatment for GBS Bacteriuria in Pregnancy

Understanding the Clinical Context

• The Centers for Disease Control and Prevention (CDC) guidelines note that GBS bacteriuria at any concentration is a marker for heavy genital tract colonization and significantly increases the risk of early-onset neonatal GBS disease 26
• Lower concentrations (<10⁴ CFU/mL) of GBS in urine can be associated with vaginal-rectal colonization 26, 27

Evidence on Low Colony Count GBS Bacteriuria

• One Utah study found elevated risk for early-onset GBS disease among infants born to women with low colony-count GBS bacteriuria compared to those without GBS bacteriuria 28, 26

Treatment Algorithm

• The CDC recommends that all pregnant women with GBS bacteriuria at any concentration during any trimester must receive IV antibiotic prophylaxis during labor 26
• Intrapartum prophylaxis must be administered ≥4 hours before delivery for maximum effectiveness, and when given ≥4 hours before delivery, prophylaxis is 78% effective in preventing early-onset neonatal GBS disease 26

Special Considerations

• Women with documented GBS bacteriuria at any point in pregnancy should not be re-screened with vaginal-rectal cultures in the third trimester, as they are presumed to be GBS colonized, although this is not directly cited, the CDC guidelines express uncertainty about whether screening for low colony-count bacteriuria is cost-effective in the context of universal late antenatal screening 28, 26, 27

Treatment of GBS UTI at 25 Weeks Gestation

Immediate Treatment and Intrapartum Prophylaxis

• The Centers for Disease Control and Prevention recommends immediate antibiotic treatment of the UTI, followed by mandatory intrapartum IV antibiotic prophylaxis during labor, regardless of whether the UTI is treated today, for patients with GBS UTI at 25 weeks gestation 29, 30
• GBS bacteriuria at any concentration during pregnancy is a marker for heavy genital tract colonization and significantly increases the risk of early-onset neonatal GBS disease, according to the Centers for Disease Control and Prevention 29, 30

Intrapartum Prophylaxis Regimens

• The American College of Obstetricians and Gynecologists recommends Penicillin G 5 million units IV initially, then 2.5 million units IV every 4 hours until delivery, as the first-line intrapartum regimen for patients without penicillin allergy 29, 31
• For patients without penicillin allergy, the American College of Obstetricians and Gynecologists also recommends an alternative regimen of Ampicillin 2 g IV initially, then 1 g IV every 4 hours until delivery 29, 31

Patient Management

• The Centers for Disease Control and Prevention states that women with GBS bacteriuria at any point during pregnancy are presumed to be heavily colonized and automatically qualify for intrapartum prophylaxis 29, 30
• The Centers for Disease Control and Prevention advises against assuming that treating the UTI eliminates the need for intrapartum prophylaxis, as this is a common and dangerous error 29, 30

Documentation and Communication

• The Centers for Disease Control and Prevention recommends ensuring that laboratory reports of GBS bacteriuria are communicated to both the anticipated site of delivery and the ordering provider 29

Treatment of Group B Streptococcal UTI at 25 Weeks Gestation

Intrapartum Prophylaxis

• The Centers for Disease Control and Prevention recommends that all pregnant women with GBS bacteriuria at any point during pregnancy must receive intrapartum IV antibiotic prophylaxis during labor, regardless of whether the UTI was treated earlier 32
• Penicillin G 5 million units IV initially, then 2.5-3.0 million units IV every 4 hours until delivery is the preferred intrapartum regimen, as recommended by the Centers for Disease Control and Prevention 32
• Intrapartum prophylaxis must be administered ≥4 hours before delivery for maximum effectiveness, resulting in a 78% reduction in early-onset neonatal GBS disease, according to the Centers for Disease Control and Prevention 32

Antibiotic Resistance

• Resistance to clindamycin ranges from 3-15% in GBS isolates, making susceptibility testing essential, as reported by the Centers for Disease Control and Prevention 33

Alternative Intrapartum Regimens

• For non-high-risk allergy, Cefazolin 2 g IV initially, then 1 g IV every 8 hours until delivery is an alternative regimen, as recommended by the Centers for Disease Control and Prevention 32
• For high-risk allergy with susceptible isolate, Clindamycin 900 mg IV every 8 hours until delivery is an alternative regimen, according to the Centers for Disease Control and Prevention 32
• For high-risk allergy with resistant or unknown susceptibility, Vancomycin 1 g IV every 12 hours until delivery is an alternative regimen, as recommended by the Centers for Disease Control and Prevention 32

Management of Vaginal Gram-Positive Cocci in Pregnancy

Critical Context: When GBS Treatment IS and IS NOT Indicated

• The Centers for Disease Control and Prevention recommends that oral or IV antibiotics given before labor are completely ineffective at eliminating GBS colonization and should never be used for asymptomatic vaginal colonization 34, 35
• The American Academy of Family Physicians states that all pregnant women with documented GBS colonization on vaginal-rectal culture at 35-37 weeks must receive IV antibiotics during active labor 36

Screening Recommendations

• The American College of Obstetricians and Gynecologists recommends collecting vaginal-rectal swabs at 36 0/7-37 6/7 weeks gestation using a single swab or two separate swabs 36
• The Centers for Disease Control and Prevention suggests that swabbing the lower vagina first, then inserting the same swab through the anal sphincter into the rectum, increases GBS detection 37, 35

Risk Factors for Early-Onset Neonatal GBS Disease

• The Centers for Disease Control and Prevention reports that maternal GBS colonization increases neonatal disease risk 29-fold compared to non-colonized mothers 37
• The American Academy of Pediatrics notes that prematurity, prolonged membrane rupture, and intrapartum fever each increase risk approximately 7-fold 37, 35

Common Pitfalls to Avoid

• The American College of Obstetricians and Gynecologists advises against prescribing oral antibiotics for asymptomatic GBS vaginal colonization during pregnancy, as this is ineffective and harmful 34, 35
• The Centers for Disease Control and Prevention recommends that laboratories use selective broth medium with overnight incubation, then subculture onto blood agar, to increase GBS detection 36, 35

Treatment of Group B Streptococcus UTI in Pregnancy

Intrapartum Prophylaxis Regimens

• The Centers for Disease Control and Prevention recommends penicillin G 5 million units IV initially, then 2.5-3.0 million units IV every 4 hours until delivery for women without penicillin allergy 38
• The Centers for Disease Control and Prevention recommends ampicillin 2 g IV initially, then 1 g IV every 4 hours until delivery as an acceptable alternative for women without penicillin allergy 38
• The Centers for Disease Control and Prevention recommends cefazolin 2 g IV initially, then 1 g IV every 8 hours until delivery for women with penicillin allergy who are not at high risk for anaphylaxis 38
• The Centers for Disease Control and Prevention recommends clindamycin 900 mg IV every 8 hours until delivery if the isolate is confirmed susceptible for women at high risk for anaphylaxis 38
• The Centers for Disease Control and Prevention recommends vancomycin 1 g IV every 12 hours until delivery if the isolate is resistant to clindamycin or susceptibility is unknown for women at high risk for anaphylaxis 38

Key Management Points

• Women with GBS bacteriuria at any point during pregnancy should not be re-screened with vaginal-rectal cultures at 35-37 weeks and are presumed to be GBS colonized, automatically qualifying for intrapartum prophylaxis, according to the Centers for Disease Control and Prevention 38

Special Pregnancy Scenarios

• The Centers for Disease Control and Prevention recommends that women admitted with signs and symptoms of preterm labor (<37 weeks) with GBS bacteriuria should receive GBS prophylaxis immediately at hospital admission 39
• The Centers for Disease Control and Prevention recommends ampicillin 2 g IV once, followed by 1 g IV every 6 hours for at least 48 hours for preterm premature rupture of membranes (PPROM) 39

Treatment of Group B Streptococcus UTI in Pregnant Women

Importance of Pregnancy Status

• The CDC guidelines emphasize that any concentration of GBS in urine during pregnancy indicates heavy genital tract colonization and significantly increases risk of early-onset neonatal GBS disease, highlighting the need for immediate treatment and intrapartum prophylaxis during labor 40, 41

Intrapartum Prophylaxis

• All pregnant women with GBS bacteriuria at ANY concentration during ANY trimester must receive IV antibiotic prophylaxis during labor, regardless of whether the UTI was treated earlier in pregnancy, as treating the UTI does not eliminate GBS colonization from the genitourinary tract 40, 41
• The CDC recommends that intrapartum prophylaxis must be administered ≥4 hours before delivery for maximum effectiveness, and when given ≥4 hours before delivery, prophylaxis is 78% effective in preventing early-onset neonatal GBS disease 40, 41

Penicillin Administration for GBS During Labor

Benefits of Intrapartum Penicillin Prophylaxis

• Intrapartum penicillin G prophylaxis for GBS-positive pregnant women is highly effective and strongly recommended, reducing early-onset neonatal GBS disease by 78-80% when administered ≥4 hours before delivery, with minimal maternal risks beyond rare anaphylaxis (approximately 5 per 10,000 treatments), as recommended by the Centers for Disease Control and Prevention (CDC) 42, 43, 44
• The American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP) endorse penicillin G 5 million units IV initially, then 2.5-3.0 million units IV every 4 hours until delivery as the preferred regimen 42, 43

Optimal Timing and Dosing

• The CDC recommends administration of penicillin G at least 4 hours before delivery to provide maximum effectiveness, though even shorter durations achieve therapeutic levels 44

Alternative Regimens for Penicillin Allergy

• For women without high-risk allergy symptoms, the CDC and ACOG recommend cefazolin 2 g IV initially, then 1 g IV every 8 hours until delivery as the preferred alternative 42, 43
• For women with high-risk allergy symptoms, the CDC and ACOG recommend clindamycin 900 mg IV every 8 hours until delivery if the GBS isolate is confirmed susceptible to both clindamycin and erythromycin 42, 43
• The CDC and ACOG also recommend vancomycin 1 g IV every 12 hours until delivery if susceptibility is unknown or the isolate is resistant to clindamycin 42, 43

Critical Clinical Pitfalls to Avoid

• The CDC and ACOG advise against treating GBS colonization with oral or IV antibiotics before labor, as such treatment is ineffective in eliminating carriage and may cause adverse consequences including antibiotic resistance 42, 43
• Healthy-appearing infants >38 weeks' gestation whose mothers received >4 hours of intrapartum antibiotic prophylaxis may be discharged as early as 24 hours after delivery if other discharge criteria are met and appropriate home observation is available, as recommended by the AAP and CDC 44

Antibiotic Selection for Group B Streptococcus UTI

High-Risk Allergy Management

• For patients with a high-risk penicillin allergy, the Centers for Disease Control and Prevention recommends obtaining clindamycin and erythromycin susceptibility testing immediately, as clindamycin resistance ranges from 3-15% and erythromycin resistance is 7-21% among GBS isolates 45, 46
• If susceptible to both clindamycin and erythromycin, clindamycin 900 mg IV every 8 hours is recommended, while vancomycin 1 g IV every 12 hours is recommended if resistant to either or susceptibility is unknown 45, 46

Laboratory Considerations

• The Centers for Disease Control and Prevention notes that beta-hemolytic streptococci are predictably susceptible to penicillin and other beta-lactams, with universal penicillin susceptibility documented in all studies worldwide 46
• Susceptibility testing must be requested within 3 days for patients with a high-risk penicillin allergy, including clindamycin and erythromycin susceptibility testing, and D-zone testing should be performed on isolates that are erythromycin-resistant but clindamycin-susceptible to detect inducible clindamycin resistance 45, 46

Treatment of Group B Streptococcal UTI in Pregnant Women

Immediate Treatment and Intrapartum Prophylaxis

• For women with preterm labor (<37 weeks) and GBS bacteriuria, GBS prophylaxis should be administered immediately at hospital admission, and discontinued if the patient is not in true labor, as recommended by the Centers for Disease Control and Prevention (CDC) 47
• In cases of preterm premature rupture of membranes (PPROM), ampicillin 2 g IV once, followed by 1 g IV every 6 hours for at least 48 hours, is adequate for both latency and GBS prophylaxis, according to the CDC 47

Intrapartum Prophylaxis Effectiveness

• Intrapartum prophylaxis must be administered ≥4 hours before delivery for maximum effectiveness, with a reported effectiveness of 78% in preventing early-onset neonatal GBS disease when given ≥4 hours before delivery 47

Guidelines for Management of Group B Streptococcus Bacteriuria in Pregnancy

Immediate Treatment and Intrapartum Prophylaxis

• All pregnant individuals with any concentration of GBS isolated from urine must receive prompt treatment of the urinary tract infection and mandatory intravenous intrapartum antibiotic prophylaxis, irrespective of symptoms or colony count. The CDC’s 1996 recommendations classify this as a strong recommendation. 48

Risk Implications of GBS Bacteriuria

• Detection of GBS bacteriuria at any level during pregnancy signifies heavy genital‑tract colonization and markedly raises the risk of early‑onset neonatal GBS disease, supporting the need for intrapartum prophylaxis. This is a strong recommendation from the CDC. 48

Special Pregnancy Scenarios

• Preterm labor (< 37 weeks): GBS prophylaxis should be initiated immediately upon hospital admission and discontinued if the patient is not in true labor, as advised by the CDC’s 2010 guidance. 49
• Preterm premature rupture of membranes (PPROM): A regimen of Ampicillin 2 g IV once followed by 1 g IV every 6 hours for at least 48 hours provides both latency support and adequate GBS prophylaxis, per CDC 2010 recommendations. 49

Limitations of Oral Antibiotics for Prophylaxis

• Oral antibiotics administered before labor do not eradicate GBS colonization and are insufficient for intrapartum prophylaxis; intrapartum intravenous therapy remains required, according to CDC 2010 guidance. 49

Management of Group B Streptococcus Urinary Tract Infection in Non‑Pregnant Adults

Indications for Antimicrobial Therapy

• Treat GBS bacteriuria in non‑pregnant patients only when the patient is scheduled for an endoscopic urologic procedure that involves mucosal trauma. Infectious Diseases Society of America (IDSA) guideline – strong recommendation, moderate‑quality evidence. 50

Scenarios Where Treatment Is Not Recommended

• Asymptomatic bacteriuria (ASB) in non‑pregnant adults should not be treated, regardless of a positive GBS urine culture. IDSA guideline – strong recommendation, moderate‑quality evidence. [50][51]52

• Specific patient groups in whom ASB should not be treated:

  • Adults with diabetes mellitus. European Association of Urology (EAU) guidance – strong recommendation. 53
  • Elderly or institutionalized individuals. IDSA guideline – strong recommendation. [50][53]
  • Patients with indwelling urinary catheters (short‑term or long‑term). IDSA guideline – strong recommendation. [54][55]50
  • Individuals with neurogenic bladder on intermittent catheterization. IDSA guideline – strong recommendation. 55
  • Patients undergoing non‑urologic surgery (including orthopedic/arthroplasty). IDSA guideline – strong recommendation. [52][53]
  • Patients with a history of recurrent UTIs. EAU guidance – strong recommendation. 53

• The 2019 IDSA guidelines state that treating ASB leads to unnecessary antibiotic exposure, increased resistance, and adverse drug effects without any clinical benefit. IDSA guideline – strong recommendation, moderate‑quality evidence. [50][51]

Antimicrobial Susceptibility Data Relevant to Therapy

• Cephalothin (a first‑generation cephalosporin) shows 100 % susceptibility among GBS isolates. IDSA guideline – level A‑I evidence. 54

Catheter‑Associated Considerations

• Do NOT screen for or treat catheter‑associated asymptomatic bacteriuria (CA‑ASB) in patients with short‑ or long‑term indwelling catheters. IDSA guideline – strong recommendation, level A‑I evidence. 54

• Exceptions to the above rule:

  • Pregnant women and
  • Patients undergoing urologic procedures with anticipated mucosal bleeding. IDSA guideline – strong recommendation. [54][55]

• When a catheter has been in place ≥ 2 weeks and the patient develops symptomatic catheter‑associated UTI, the catheter should be replaced before initiating antimicrobial therapy. IDSA guideline – strong recommendation. 55

Guideline Recommendations for Group B Streptococcus (GBS) Screening and Intrapartum Antibiotic Prophylaxis

Screening Protocol

Indications for Intrapartum Antibiotic Prophylaxis (IAP)

Antibiotic Regimens

Women Without Penicillin Allergy

Women With Low‑Risk Penicillin Allergy

Women With High‑Risk Penicillin Allergy

Laboratory Reporting for GBS Bacteriuria

Critical Pitfalls to Avoid

Intrapartum Antibiotic Prophylaxis for Group B Streptococcus (CDC Guidelines)

Recommended First‑Line Regimen (No Penicillin Allergy)

• The CDC recommends administering penicillin G 5 million units IV initially, then 2.5–3.0 million units IV every 4 hours until delivery as the preferred intrapartum antibiotic for women colonized with GBS. 57, 58
• Ampicillin 2 g IV initially, then 1 g IV every 4 hours until delivery is an acceptable alternative when penicillin G is unavailable. 57, 58

Timing and Expected Effectiveness

• Achieving at least 4 hours of antibiotic exposure before delivery maximizes protection, reducing early‑onset neonatal GBS disease by 78–89 %. 57
• While 4 hours is optimal, the CDC advises not to delay medically necessary obstetric procedures solely to reach this interval; prophylaxis should be given as soon as labor begins. 57, 58

Regimens for Penicillin‑Allergic Patients

Low‑Risk Allergy (no anaphylaxis, angioedema, respiratory distress, or urticaria)

• Cefazolin 2 g IV initially, then 1 g IV every 8 hours until delivery is the preferred alternative for patients with low‑risk penicillin allergy. 57, 58

High‑Risk Allergy (history of anaphylaxis, angioedema, respiratory distress, or urticaria)

• Susceptibility testing for clindamycin and erythromycin must be performed on the maternal GBS isolate before selecting an alternative agent. 58
• If the isolate is susceptible to both clindamycin and erythromycin, give clindamycin 900 mg IV every 8 hours until delivery. 57, 58
• If the isolate is resistant to either agent or susceptibility is unknown, administer vancomycin 1 g IV every 12 hours until delivery. 57, 58
• When the isolate is susceptible to clindamycin but resistant to erythromycin, perform D‑zone testing to detect inducible clindamycin resistance; clindamycin may be used only if the D‑zone test is negative. 58
• Erythromycin is no longer an acceptable alternative for intrapartum prophylaxis in high‑risk penicillin‑allergic women. 57, 58

Clindamycin Resistance and Requirement for Susceptibility Testing in Group B Streptococcus Urinary Tract Infections

Antibiotic Susceptibility

CDC Recommendations for Group B Streptococcus Prophylaxis in Women Presenting with Preterm Labor (< 34 weeks)

Immediate Initiation of Prophylaxis

• In women presenting with preterm labor before 34 weeks gestation and an unknown GBS colonization status, the CDC advises starting intravenous penicillin G (or ampicillin when penicillin is unavailable) immediately upon hospital admission and continuing the regimen until delivery or until preterm labor is ruled out【60】.
• For any woman showing signs and symptoms of preterm labor before 37 weeks gestation with either unknown or positive GBS status, prophylactic antibiotics should be initiated at admission without awaiting culture results【60】.
• The CDC explicitly recommends that clinicians do not delay the start of intrapartum GBS prophylaxis while awaiting screening results in this high‑risk scenario【60】.

Timing and Screening Considerations

• The CDC emphasizes that a negative GBS culture obtained in a prior pregnancy does not confer protection in the current pregnancy; each pregnancy requires its own screening to guide prophylaxis decisions【60】.

Common Pitfalls to Avoid

• According to CDC guidance, treating asymptomatic GBS colonization with oral antibiotics before labor is ineffective for eradicating carriage, does not prevent neonatal disease, and contributes to antibiotic resistance【60】.

Management of Group B Streptococcus Bacteriuria in Non‑Pregnant Adults

Guideline Recommendations (IDSA)

• The 2019 Infectious Diseases Society of America (IDSA) guidelines strongly recommend against treating asymptomatic bacteriuria in non‑pregnant adults, even when patients report nonspecific symptoms such as malaise. 61, 62
• Antibiotic therapy is only indicated when classic urinary symptoms (dysuria, frequency, urgency, suprapubic pain, flank tenderness) or systemic signs of infection (fever, rigors, hemodynamic instability) are present and no alternative source of infection is identified. 62

Evidence of Harm from Unnecessary Treatment

• Observational data show that nonspecific symptoms (malaise, fatigue, confusion) in patients with bacteriuria are more often linked to underlying host factors rather than a true urinary infection. 62
• In hospitalized patients with asymptomatic bacteriuria and delirium, antimicrobial treatment did not improve outcomes and was associated with a higher risk of Clostridioides difficile infection. 62
• Treating asymptomatic bacteriuria leads to unnecessary antibiotic exposure, promotion of antimicrobial resistance, and increased adverse drug events (including C. difficile) without measurable clinical benefit. 61, 62
• A cohort of delirious hospitalized patients demonstrated worse functional recovery when treated for asymptomatic bacteriuria (adjusted odds ratio ≈ 3.5). 62

Situations Where Treatment Is Not Recommended

• Patients presenting only with nonspecific symptoms (e.g., malaise, fatigue) without urinary symptoms should not receive antibiotics. 61, 62
• Elderly or institutionalized individuals who have only nonspecific symptoms should also not be treated for bacteriuria. 62

Clinical Decision‑Making and Pitfalls

• Decision algorithms advise that malaise alone, without dysuria, is insufficient to justify antimicrobial therapy; clinicians should instead evaluate alternative causes of malaise. 61, 62
• Recommended evaluation of other potential etiologies for malaise includes dehydration, electrolyte disturbances, anemia, thyroid dysfunction, depression, and medication side effects. 62
• A frequent pitfall is prescribing antibiotics for non‑pregnant patients with GBS bacteriuria and malaise in the absence of urinary symptoms, which results in unnecessary antibiotic exposure and contributes to resistance. 61, 62

Intrapartum Antibiotic Prophylaxis for Group B Streptococcus in Pregnancy

Indications for Prophylaxis

• The CDC recommends that any pregnant individual with Streptococcus agalactiae (GBS) isolated from vaginal specimens—whether representing colonization or symptomatic aerobic vaginitis—receive intrapartum intravenous antibiotic prophylaxis during labor to prevent early‑onset neonatal GBS disease. 63

Standard Prophylactic Regimen

• The CDC’s standard intrapartum regimen is penicillin G 5 million units IV as a loading dose, followed by 2.5 million units IV every 4 hours until delivery; the antibiotics should be administered for at least 4 hours before birth to achieve 78–89 % effectiveness in preventing neonatal infection. 63

Management of Penicillin Allergy

• Low‑risk allergy (no history of anaphylaxis, angioedema, or urticaria): the CDC advises cefazolin 2 g IV initially, then 1 g IV every 8 hours for intrapartum prophylaxis. 63
• High‑risk allergy (history of anaphylaxis or severe immediate reactions): the CDC recommends obtaining clindamycin and erythromycin susceptibility testing on the GBS isolate immediately. 63
• If the isolate is susceptible to both clindamycin and erythromycin, the CDC recommends clindamycin 900 mg IV every 8 hours until delivery. 63
• If the isolate is resistant to either agent or susceptibility is unknown, the CDC recommends vancomycin 1 g IV every 12 hours until delivery. 63

Avoidance of Unnecessary Antibiotic Use

• According to American Family Physician, asymptomatic vaginal GBS colonization in non‑pregnant individuals should not be treated with oral or intravenous antibiotics, because such treatment does not eradicate carriage, promotes antimicrobial resistance, and offers no clinical benefit. 64

Management of Group B Streptococcus Bacteriuria in Pregnancy

Risk Assessment & Indications for Treatment

• Any detection of GBS in the urine of a pregnant woman mandates immediate treatment of the urinary infection and obligates intrapartum intravenous prophylaxis, regardless of symptom status. The CDC (MMWR Recommendations and Reports) states this as a universal requirement. 65
• GBS bacteriuria at any concentration during any trimester serves as a marker of heavy genital‑tract colonisation and markedly raises the risk of early‑onset neonatal GBS disease. This risk assessment underpins the need for prophylaxis. 65

Intrapartum Antibiotic Prophylaxis (IAP) – General Principle

• All pregnant patients with documented GBS bacteriuria at any point in the current pregnancy must receive intravenous IAP during labor, even if the urinary infection was previously treated. This recommendation applies irrespective of the timing of the bacteriuria detection. 65

Standard IAP Regimen (No Penicillin Allergy)

• Penicillin G 5 million units IV as a loading dose, followed by 2.5–3.0 million units IV every 4 hours until delivery is the preferred regimen. 65
• Ampicillin 2 g IV initially, then 1 g IV every 4 hours until delivery is an acceptable alternative when penicillin is unavailable or contraindicated. 65
• Administer the prophylactic antibiotic at least 4 hours before delivery to achieve maximal effectiveness; this timing yields an estimated 78 % reduction in early‑onset neonatal GBS disease. 65

IAP for Penicillin‑Allergic Patients

• Low‑risk allergy (no anaphylaxis, angioedema, or urticaria): use cefazolin 2 g IV initially, then 1 g IV every 8 hours until delivery. 65
• High‑risk allergy (history of anaphylaxis or severe immediate reaction): obtain clindamycin and erythromycin susceptibility testing immediately.
  
  • If the isolate is susceptible to both agents: give clindamycin 900 mg IV every 8 hours until delivery. 65
  • If resistant or susceptibility is unknown: give vancomycin 1 g IV every 12 hours until delivery. 65

Additional Pregnancy‑Specific Considerations

• Women with GBS bacteriuria do not require routine vaginal‑rectal screening cultures at 35–37 weeks gestation because they are automatically classified as candidates for IAP. 65

Critical Pitfalls (Safety Alerts)

• Do not treat asymptomatic GBS vaginal or urethral colonisation with oral or IV antibiotics before labor in pregnant women; such treatment does not eradicate carriage, promotes resistance, and fails to prevent neonatal disease. This safety warning is emphasized by both the 2002 and 2010 CDC (MMWR) recommendations. [66][65]

All statements are derived from CDC (MMWR Recommendations and Reports) guidelines, which constitute strong, evidence‑based recommendations for the management of GBS bacteriuria in pregnancy.

Postpartum Antibiotic Use After Intrapartum Group B Streptococcus (GBS) Prophylaxis

General Recommendations

• The CDC recommends that ampicillin (or penicillin G) administered for intrapartum GBS prophylaxis should be stopped at delivery in women who remain asymptomatic; routine postpartum continuation is not advised. 67

• Intrapartum GBS prophylaxis is intended solely to prevent vertical transmission of GBS to the neonate; the protective effect ends once the birth is completed. 68

• CDC guidelines specify that the antibiotic regimen is to be given until delivery and do not include any recommendation for postpartum continuation in the absence of maternal infection. 67

Effectiveness of Intrapartum Prophylaxis

• Achieving therapeutic antibiotic concentrations in amniotic fluid and fetal circulation requires at least 4 hours of infusion before delivery; this timing yields an estimated 78 % reduction in early‑onset neonatal GBS disease. 67, 69, 70

• After the infant is born, the pharmacologic mechanism that blocks neonatal colonization no longer applies, eliminating any further benefit from continued dosing. 68

When Postpartum Antibiotics Are Indicated

• Postpartum antibiotic therapy should be initiated only if the mother develops clinical signs of infection (e.g., suspected chorioamnionitis or postpartum endometritis). 71

• If chorioamnionitis was suspected during labor, the mother should have received a broader‑spectrum regimen (ampicillin + gentamicin) intrapartum; continuation of this regimen postpartum may be warranted based on ongoing clinical assessment. 71, 69

• Treatment of confirmed maternal infection (chorioamnionitis or endometritis) requires broader‑spectrum antibiotics and should be continued postpartum until the infection resolves clinically. 71, 68

Special Clinical Scenarios

• GBS bacteriuria during pregnancy – Even if bacteriuria was treated earlier, intrapartum IV prophylaxis remains required; postpartum antibiotics are not indicated unless the woman becomes symptomatic. 67

• Preterm premature rupture of membranes (PPROM) – When ampicillin is used for latency prolongation, the course is limited to 48 hours (2 g IV once, then 1 g IV every 6 h) and is not routinely extended after delivery. 67

Distinguishing Prophylaxis from Treatment

• Intrapartum GBS prophylaxis and treatment of maternal infection are separate indications with different durations: prophylaxis ends at delivery, whereas treatment continues postpartum until clinical cure. 67

• A positive GBS colonization status alone does not justify postpartum antibiotic use; only overt signs of infection warrant additional therapy. 68

• GBS colonization is not an infection and therefore does not require antimicrobial therapy outside the intrapartum window. 67

Antibiotic Recommendations for Group B Streptococcus (GBS) in Penicillin‑Allergic Patients and Intrapartum Prophylaxis

Alternative Regimens for Penicillin Allergy

• Cefazolin is the preferred first‑line alternative for individuals with low‑risk penicillin allergy (no history of anaphylaxis, angioedema, respiratory distress, or urticaria). The CDC recommends using cefazolin because cross‑reactivity with penicillins is low and first‑generation cephalosporins retain near‑universal GBS susceptibility. 72

• Clindamycin should be used only after confirming isolate susceptibility; resistance rates range from 3 % to 15 % and are rising. The CDC advises susceptibility testing before selecting clindamycin for high‑risk penicillin‑allergic patients. 72

• When both clindamycin and erythromycin susceptibility are demonstrated, clindamycin is the preferred agent. This recommendation follows CDC guidance for high‑risk allergic patients. 72

• D‑zone testing is required for isolates that are erythromycin‑resistant but appear clindamycin‑susceptible, to detect inducible clindamycin resistance. The CDC mandates this phenotypic test to avoid therapeutic failure. 72

• Vancomycin should be reserved for situations where the isolate is clindamycin‑resistant, susceptibility is unknown, or no other suitable agents exist. The CDC positions vancomycin as a last‑line option in penicillin‑allergic patients. 72

• Erythromycin is no longer recommended for prophylaxis or treatment in penicillin‑allergic patients because resistance rates are 7 %–21 % and macrolide resistance is increasing. CDC guidance reflects current resistance trends. 72

• Empiric use of erythromycin or clindamycin without susceptibility testing is discouraged, as resistance can exceed 12 % for erythromycin and 7 % for clindamycin. This CDC warning emphasizes the need for laboratory confirmation. 72

Intrapartum Prophylaxis for Pregnant Individuals

• Standard intrapartum prophylaxis for GBS‑colonized pregnant individuals consists of penicillin G 5 million units IV initially, followed by 2.5–3.0 million units IV every 4 hours until delivery. The CDC recommends this dosing regimen to achieve adequate maternal and neonatal drug levels. [73][74]72

• Pregnant individuals with GBS bacteriuria at any concentration during any trimester require immediate treatment of the urinary infection and mandatory intrapartum IV prophylaxis, regardless of prior therapy. CDC guidance mandates both therapeutic and preventive measures in this high‑risk group. [73][74]